A carregar...
Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives
Approximately 5%–10% of asthmatics suffer from severe asthma. New biological treatments represent a great opportunity to reduce asthma burden and to improve asthma patients’ lives. Reslizumab will soon be available in several European countries. This anti-IL-5 IgG4/κ monoclonal antibody, administere...
Na minha lista:
| Publicado no: | Patient Relat Outcome Meas |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6103306/ https://ncbi.nlm.nih.gov/pubmed/30147386 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PROM.S146966 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|